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Abstract
Background: Travellers visiting friends and relatives (VFR) define a specific population of travellers exposed to
higher risks for health and safety than tourists. The aim of this study was to assess differentials in pre-travel health
care in VFR travellers compared to other travellers.
Methods: A retrospective cohort study was performed including attendees of the Travel Medicine Clinic of the
Hospital Universitari de Bellvitge, Barcelona, Spain, between January 2007 and December 2017.
Results: Over the 10-year period, 47,022 subjects presented to the travel clinic for pre-travel health care, 13.7% of
whom were VFR travellers. These showed higher rates of vaccination against yellow fever and meningococcus, but
lower rates for hepatitis A, hepatitis B, influenza, rabies, cholera, polio, typhoid IM vaccine and tetanus vaccine
boosters. Regarding malaria prevention measures, results highlighted that VFR travellers, when compared with
tourists, were more likely to be prescribed with chemoprophylaxis, particularly with mefloquine, than with atovaquone/
proguanil.
Conclusions: Findings from this large-scale study indicated differences in vaccination rates and completion, as well as
in chemoprophylaxis for malaria, between VFR and non-VFR travellers, fostering specific interventions for promoting
adherence to pre-travel health advice among migrant travellers.
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Background
According to the United Nations, the number of inter-
national refugees and migrants worldwide has continued
to grow rapidly in recent years, reaching 258 million in
2017, with a number of migrants as a percentage (14%)
of the population residing in high-income countries [1].
As a consequence of this geographic dispersion through
movement of people, migrants who return to their place
of origin represent a large number of international trav-
ellers, also forecasted to increase. Indeed, the public
health construct “visiting friends and relatives (VFR)”
categorises travellers—often ethnically distinct from the
majority population of the country of residence—who
travel to lower-income countries for the purpose of visit-
ing friends and relatives [2, 3].
VFR travellers are exposed to higher risk of travel-
related health problems than other travellers. Reasons
for this risk variance are many. They generally stay lon-
ger than tourists in the country of destination, go to
rural and higher-risk areas, have close contact with the
local population, as well as are subject to local social and
cultural practices (such as consuming high-risk foods
and water served by hosts, type of accommodation and
so on) [4].
Again, despite being at considerable risk for their
health and safety, VFR travellers showed lower levels use
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of pre-travel health services and less adherence to pre-
travel advice. Drivers for not consulting health profes-
sional before travelling were the underestimation of
risks, including a scares knowledge of the disease and
the perception that the measures undertaken would be
sufficient, the belief of being experienced travellers, as
well as financial limitations of the migrant population
[5]. Moreover, in this susceptible traveller population,
assessing previous exposure and immunisation and vac-
cination status is complicated by several cultural and so-
cioeconomic barriers [6–8].
Yet, to the best of our knowledge, the information
focusing on pre-travel assessment of VFR travellers cur-
rently available is limited, with little or no epidemiological
studies conducted on a large scale in Europe and over
time [9]. A recent small-scale study on the use of pre-
travel health among VFR travellers, conducted in the
United States, highlighted differentials in the level of pre-
travel care between VFR and non-VFR individuals and
lower vaccination rates in the VFR population [10].
Therefore, this study aimed to describe differences in
the usage of pre-travel health care among different trav-
eller cohorts over a 10-year period.
Methods
This retrospective cohort study was conducted at the
Travel Medicine Clinic of the Hospital Universitari de
Bellvitge, in Barcelona, Spain, including attendees in the
travel clinic between January 2007 and December 2017.
The clinic is part of the public Catalan Health Service,
with the price for pre-travel visit and vaccine administra-
tion (one or different types of vaccines) established as
per national policies, as well as with a full coverage of
the prescribed antimalarial chemoprophylaxis.
Pre-travel counselling was provided by travel medicine
specialists of the unit and included information and rec-
ommendations of safety and health travels, in accordance
with U.S. Centres for Disease Control and Prevention
(CDC) guidelines [4], comprising vaccine indications, food
safety, diarrhoea prevention, and information about the
implementation of interventions to avoid mosquito bites
(such as mosquito nets, use of repellent, and appropriate
clothes) and malaria chemoprophylaxis.
The Institutional Ethical Review Board approved the
study protocol and granted approval for reviewing re-
cords for the purpose of the study. Confidentiality was
maintained by omitting any personal identifying infor-
mation from data collection.
From the travellers’ recording tool, the following data
were extracted for each individual: age, sex, area of origin,
travel destination, purpose of travel (VFR and non-VFR,
such as tourism and leisure, business, etc.), vaccines admin-
istered and prescription for malaria chemoprophylaxis.
The medical records reported the administration and
completion of the following routine or travel-related
vaccines: hepatitis A, hepatitis B, typhoid fever, yellow
fever, meningococcus, polio, rabies, cholera, influenza,
measles-mumps-rubella (MMR), tetanus and diphtheria-
tetanus-pertussis (DTPa). Attendees refusing a recom-
mended vaccine were considered not vaccinated.
Data on malaria prevention measures recorded partici-
pants who were prescribed mefloquine 250 mg or atova-
quone 250 mg and proguanil 100mg. Dosage of the
medications used for chemoprophylaxis followed the
recommendation provided by the CDC. Travellers pre-
scribed with mefloquine were instructed to begin
chemoprophylaxis 2 weeks before travel to malarious
areas, continue once a week during travel in malarious
areas and for 4 weeks after their return. Atovaquone/
proguanil was prescribed to be started 1–2 days before
travel to malarious areas and taken daily while in the
malarious areas and for 7 days after leaving the area [4].
Continuous variables were expressed as mean and
standard deviation (SD); categorical variables were de-
scribed as number and percentage. The Student’s t-test
for independent samples was used to assess differences be-
tween means; the chi-squared (χ2) test was used to assess
differences between categories. Univariate analyses were
also conducted to determinate vaccine completion and
anti-malarial prescription between VFR and non-VFR
travellers. Subsequently, independent variables (age, sex
and travel destination) were included in a multivariate lo-
gistic regression model to adjust for potential confounders
and estimate the likelihood of vaccine completion and
anti-malarial prescription for VFR travellers. To perform
logistic regression analysis, those variables with a p-value
equal or less than 0.25 were, therefore, considered for in-
clusion. A stepwise backward selection procedure was
used, fixing a p-value of ≤0.40 as the criterion for remov-
ing variables from the final multivariate regression models.
Results were reported as crude and adjusted odds ratios
(ORs) and 95% confidence intervals (CIs). All statistical
tests were two-tailed, and a p-value ≤0.01 was considered




Over the 10-year period, 47,022 subjects attended to the
Travel Medicine Clinic of the Hospital Universitari de
Bellvitge for pre-travel health care, constituting the co-
hort included in this study. Approximately half (51.7%)
were female, with a mean age of 34.7 years (± 13.9 SD).
The vast majority of travellers were European (84.7%),
with 39,102 travellers from Spain. Regarding travel infor-
mation, the most popular destinations were Africa,
South-eastern Asia and South America. VFR travellers
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represented 13.7% of the cohort, originating mainly from
South America (49.9%) and Africa (31.7). Baseline char-
acteristics of the study population are reported in com-
parative Table 1. Comparison between VFR and non-
VFR cohorts revealed statistically significant differences
above all investigated baseline characteristics (p < 0.001
for all).
Vaccinations
Figure 1 shows the total number of travellers who were ad-
ministered vaccines, and the proportions of VFR and non-
VFR travellers. The analysis showed differences in vaccination
completion between the two groups (Table 2). Except for yel-
low fever and meningococcus vaccines, where the odds of
vaccination were about twice greater in the VFR population,
non-VFR travellers showed higher rates of vaccination against
hepatitis A, hepatitis B (first dose), influenza, rabies, cholera,
polio, typhoid IM vaccine and tetanus vaccine booster.
No significance was found in rates of completion of oral
typhoid, DTPa, MMR and of the entire series of hepatitis
B vaccines, as well as when to vaccinate hepatitis A.
Malaria prevention
Of the whole population, 16,255 were prescribed malaria
chemoprophylaxis. In general, VFR travellers were more
likely to be prescribed malaria chemoprophylaxis (43.5%
vs. 33.1%, p < 0.001). Stratified data on type of medica-
tion prescribed for the prevention of malaria showed
that, independent of travel destinations, non-VFR travel-
lers had a better than 28% chance of receiving atova-
quone/proguanil prescription, whereas VFR travellers
were more likely to be prescribed mefloquine (Table 3).
Discussion
This large-scale study, the first performed in Spain,
offers a first important insight into differences in vaccin-
ation between VFR and non-VFR travellers.
It is important to remember that the VFR population
differs from travellers other than VFR in sociodemo-
graphic characteristics. These travellers, in fact, were
younger than non-VFR travellers; were for the most part
women; and, as expected, composed mainly of people
from non-European countries. The analysis of vaccin-
ation rates between the two cohorts indicated some dif-
ferentials in adherence to immunisation protocols. First
of all, it should be noted that the level of completion of
those vaccines was not properly related to travel. Indeed,
vaccines against influenza, polio, tetanus and both hepa-
titis A/B and hepatitis B were less likely to be completed
by VFR travellers. Regarding hepatitis, noticeable is the
Table 1 Baseline characteristics of study participants (n = 47,022)
All (n = 47,022) Non-VFR (n = 40,569) VFR (n = 6453) Comparison
N (column %) N (column %) N (column %) P value°
Sex < 0.001
Male 22,712 (48.3) 20,224 (49.8) 2488 (38.6)
Female 24,310 (51.7) 20,345 (50.2) 3965 (61.4)
Agea 34.7 ± 13.9 35.8 ± 12.5 28.7 ± 18.7 < 0.001
Area of origin < 0.001
Africa 2257 (4.8) 215 (0.5) 2042 (31.7)
Asia 752 (1.6) 124 (0.3) 628 (9.7)
Australia 19 (0.0) 12 (0.0) 6 (0.1)
Europe 39,828 (84.7) 39,764 (98.0) 64 (1.0)
North America 28 (0.1) 20 (0.1) 8 (0.1)
Cen. America 517 (1.1) 36 (0.1) 481 (7.5)
South America 3621 (7.7) 397 (1.0) 3223 (49.9)
Travel destination < 0.001
Africa 14,859 (31.6) 12,779 (31.5) 2080 (32.2)
Asia 6301 (13.4) 5842 (14.4) 459 (7.1)
SEA 11,614 (24.7) 11,481 (28.3) 133 (2.1)
Cen. America 3950 (8.4) 3489 (8.6) 461 (7.1)
South America 9640 (20.5) 6369 (15.7) 3270 (50.7)
Others 658 (1.4) 609 (1.5) 49 (0.8)
VFR Travellers visiting friends and relatives, SEA South-eastern Asia
°P value obtained by chi-squared (χ2) and Student’s t-tests
aMean ± standard deviation
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scarce level of vaccine completion in the VFR travellers,
since their most frequent destinations were in African
countries, where hepatitis B is spreading on an endemic
level. On this point, previous epidemiological research
highlighted that a great percentage of hepatitis B in VFR
travellers returning to their residency country are in
those coming back from Africa (mainly, from sub-
Saharan Africa), where the major epidemiological deter-
minant for hepatitis B infections in VFR travellers is rep-
resented by the higher likelihood of sexual encounters
with natives during travel [12]. However, a limitation ex-
ists because VFR travellers usually do not have a child-
hood immunisation card, so the prescription is provided
during the visit or, if some period of time exists prior to
travel, a serology is done to assess the need for immun-
isation. In Catalonia, travellers born after 1983 have
been vaccinated against hepatitis B in adolescence, and
all have a childhood immunisation card. Catalan travel-
lers born before 1983 or immigrants without a registry
about immunisation are usually prescribed hepatitis B if
the endemicity is higher than that in our country.
Migration in Catalonia started at the beginning of the
XXI century, so VFRs do not travel much more often
than non-VFR travellers. They save money from their ar-
rival to come back home as soon as possible, but it was
difficult to travel once during the first decade, because
flights were expensive [13]. Therefore, VFR and non-
VFR adults, once they are seen at the travel clinic (in a
real-life context), probably show that they have not
received any vaccine since childhood, and no immunisa-
tion history is present, so no difference between them
exists [14].
Low levels of immunisation for the other routine vac-
cines are likewise a worry; staying too long in rural areas,
in close proximity to the local population, in suboptimal
hygienic conditions, exposes travellers to diseases from
which the population should be protected [2, 3]. In this
regard, one of the most relevant challenges in the health
care of migrants is represented by the difficulty of
obtaining clear information on their immunisation status
because of partial or no data regarding previous expo-
sures or vaccinations [15]. This aspect, indeed, forms
part of the wider problems of inequalities in access to
health services in the countries where migrants live,
likely due to sociocultural, economic (costs) and lan-
guage barriers [16–18]. These are the same drivers
that—together with others (such as immunisation hesi-
tancy, low risks perception, limited time before the
travel, characteristics of the travel and so on)—could
probably lead VFR travellers to ignore pre-travel care
and advice before they travel. On the other hand, this
study can be considered a pragmatic or real-life study,
because usually adults in Catalonia do not have an im-
munisation card, and neither do immigrants.
A constant source of concern about travellers’
health is food and water safety, with special attention
to the prevention of traveller’s diarrhoea and other
food-related illnesses [19]. VFR travellers are
Fig. 1 Total number of individuals administered each vaccine (first dose) and proportions of VFR and non-VFR vaccinees. VFR, travellers visit friends
and relatives; HAV, hepatitis A; HBV, hepatitis B; MMR, measles-mumps-rubella; DTPa, diphtheria-tetanus-pertussis
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commonly exposed to these risks more than tourists,
due to eating contaminated food (crude food, fresh-
water fish and so on), sharing meals with local hosts
and limited access to water. The low level of adher-
ence to hepatitis A, typhoid IM and cholera vaccines
among VFR travellers calls attention to the potential
implications for their health. One possible explanation
for the lower vaccination rate against hepatitis A
amongst VFR travellers is that this population might
be exposed to the infection in their home-country
during childhood, reducing the need for this specific
protection. More research should deepen this aspect.
However, typhoid fever or cholera should be empha-
sised in their vaccination regimen because of an in-
creased risk of exposure in rural areas in endemic
countries.
Table 2 Rates of administration of vaccinations (n = 47,022)
All (n = 47,022) Non-VFR (n = 40,569) VFR (n = 6453)
N (%) N (%) N (%) cOR (95% CI) aOR (95% CI)a
HAV
1st dose 13,130 (27.9%) 11,469 (28.3) 1661 (25.7) 0.88 (0.83–0.93) 0.59 (0.55–0.64)
2nd dose 3024 (6.4%) 2732 (6.7) 292 (4.5) 0.66 (0.58–0.74) 0.56 (0.48–0.65)
HBV
1st dose 212 (0.5%) 198 (0.5) 14 (0.2) 0.44 (0.26–0.76) 0.35 (0.18–0.70)
2nd dose 75 (0.2%) 67 (0.2) 8 (0.1) 0.75 (0.36–1.56) 0.99 (0.46–2.17)
3rd dose 34 (0.1%) 31 (0.1) 3 (0.1) 0.61 (0.19–1.99) 0.51 (0.12–2.18)
HAV + HBV
1st dose 2039 (4.3%) 1852 (4.6) 187 (2.9) 0.62 (0.54–0.73) 0.61 (0.51–0.72)
2nd dose 442 (0.9%) 418 (1.0) 24 (0.4) 0.35 (0.24–0.54) 0.35 (0.21–0.61)
3rd dose 167 (0.4%) 150 (0.4) 17 (0.3) 0.71 (0.43–1.18) 0.73 (0.41–1.30)
Tetanus
DTPa 350 (0.7%) 307 (0.8) 43 (0.7) 0.88 (0.64–1.21) 0.85 (0.58–1.24)
Td booster 5706 (12.1%) 5109 (12.6) 597 (9.3) 0.71 (0.65–0.77) 0.66 (0.59–0.73)
Influenza 1014 (2.2%) 955 (2.4) 59 (0.9) 0.38 (0.29–0.50) 0.43 (0.28–0.64)
MMR 395 (0.8%) 326 (0.8) 69 (1.1) 1.33 (1.03–1.73) 0.77 (0.52–1.13)
Polio 3111 (6.6%) 2775 (6.8) 336 (5.2) 0.75 (0.67–0.84) 0.70 (0.61–0.81)
Yellow fever 15,558 (33.1%) 12,439 (30.7) 3119 (48.3) 2.12 (2.01–2.23) 2.00 (1.88–2.13)
Typhoid
Oral vaccine 4090 (8.7%) 3485 (8.6) 605 (9.4) 1.10 (1.01–1.20) 1.15 (1.00–1.29)
IM vaccine 30,507 (64.9%) 26,437 (65.2) 4070 (63.4) 0.91 (0.86–0.96) 0.79 (0.74–0.85)
Rabies
1st dose 1125 (2.4%) 1069 (2.6) 56 (0.9) 0.32 (0.27–0.42) 0.22 (0.16–0.31)
2nd dose 88 (0.2%) 84 (0.2) 4 (0.1) 0.30 (0.11–0.81) 0.26 (0.08–0.86)
3rd dose 51 (0.1%) 51 (0.1) 0 (0) – –
Meningococcus 5280 (11.2%) 4110 (10.1) 1170 (18.1) 1.96 (1.83–2.11) 3.01 (2.72–3.33)
Cholera 2493 (5.3%) 2278 (5.6) 215 (3.3) 0.61 (0.53–0.71) 0.68 (0.58–0.80)
VFR Travellers visit friends and relatives, HAV Hepatitis A, HBV Hepatitis B, MMR Measles-mumps-rubella, DTPa Diphtheria-tetanus-pertussis, cOR Crude odds ratio,
aOR Adjusted odds ratio, CI Confidence interval
aAdjusted for age, sex, and travel destination
Table 3 Travellers prescribed malaria chemoprophylaxis (n = 16,255)
Chemoprophylaxis
Non-VFR VFR
cOR (95% CI) aOR (95% CI)a
N (%) N (%)
Mefloquine 2829 (17.4) 1724 (10.6) 4.86 (4.55–5.20) 6.21 (5.72–6.76)
Atovaquone/Proguanil 10,582 (65.1) 1120 (6.9) 0.60 (0.56–0.64) 0.72 (0.67–0.78)
VFR Travellers visiting friends and relatives, cOR Crude odds ratio, aOR Adjusted odds ratio, CI Confidence interval
aAdjusted by age, sex, and travel destination
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Moreover, travelling to remote areas necessarily entails
a greater attention to specific risks and demands about
immunisation. One of these is represented by the in-
creased exposure to animal bites, even those kept by
local families; then protection against rabies becomes
important, especially for the high mortality rate of the
disease [20]. In this regard, VFR travellers showed sig-
nificantly less adherence to rabies vaccination than other
travellers did.
Interesting, instead, is the finding that the odds of ac-
quiring yellow fever vaccination were twice greater in
the VFR population than among non-VFR travellers,
partially in accordance with the results reported by Tan
et al. [10] but displaying a lack of concordance if com-
pared to published research conducted to assess travel
characteristics about the adherence to yellow fever vac-
cination [21]. This might be explained by the fact that
VFR travellers had planned travels to countries or areas
endemic for yellow fever, and they probably are very
conscious of the danger of the disease. Another reason
that may lead VFR travellers to acquire this vaccine is
that travellers are required to present a proof of vaccin-
ation to enter certain countries. Indeed, the requirement
of a vaccination certificate may explain the higher rate
of meningococcal vaccinations among VFR travellers.
Travel destinations and length of stay might influence
the level of prescription of antimalarial drugs between
the two groups. VFR individuals travelled more to mal-
aria zones than tourists did, so they were prescribed per-
sonal protection measures against malaria. However,
independent of travel destinations, VFR travellers re-
ceived more mefloquine than atovaquone-proguanil,
probably due to time duration, but we could not confirm
this. In South America, neither VFR nor non-VFR travel-
lers usually went to malaria-endemic areas, so we usually
did not prescribe antimalarial chemoprophylaxis.
Further studies should highlight the level and drivers
of adherence to malaria chemoprophylaxis among VFR
travellers, though. For instance, a study by Wieten et al.,
which only included VFR travellers to West Africa,
found that age was positively associated with the prob-
ability of receiving pre-travel advice, as well as was a sig-
nificant factor associated with the behaviours of buying
and starting chemoprophylaxis before departure [22].
However, it should be mentioned that the research on
the contribution of age on the adherence to malaria pre-
vention measures needs further study [23].
VFR travellers are recognised as a peculiar traveller
population, characterised by special health needs [24].
The presented findings showed a relevant gap in pre-
travel care, with alarming differences between non-VFR
and VFR travellers, and when rates of vaccination were
suboptimal in both groups. Hypothetically, several
drivers could be referred to as determinants in those
differences. First, VFR travellers could have biased atti-
tudes and perceptions about travel-related health risks,
particularly when they are living in a home country with
a low gradient of epidemiologic risks that might falsely
reassure them, also fostering the belief that they are
already immune, thus leading to less use of precautions
and fewer personal protection measures than tourists
take [4]. On this point, it is also important to highlight
that several barriers could affect the pre-travel consult-
ation. Indeed, it constitutes a complex process and its ef-
fectiveness strongly depends on relationship between
physician and traveller [25, 26]. These are often provided
with too much information, which can be misunder-
stood when communication and language barriers are
present, as in the case of VFR travellers.
Finally, it is possible to affirm that specific interven-
tions are needed to promote adherence to pre-travel
health advice among VFR travellers, pointing out health
education and health promotion for this group popula-
tion, to achieve an optimal level of protection against
travel-related risks [27, 28].
This study may have some methodological limitations
that are worthy of emphasis and that should be consid-
ered when interpreting the results. First, the cohort na-
ture of the study does not make it possible to establish
causal effects. In addition, the database information of
the travel clinic attendees did not include data on previ-
ous vaccinations (usually not recorded or registered nor
provided by travellers), comorbidities (usually travellers
say that they do not have any medical condition, and we
could not recover data about that) and characteristics
other than those mentioned in the Methods section: the
possibility that associations found may be explained by
other confounders should be taken into account. Second,
the study includes only subjects seeking medical advice
in our unit and does not include patients seeking it else-
where or not seeking it at all, so this cohort might be in-
adequate for determining all the predictors of vaccines
and chemoprophylaxis acceptance. Further studies on
this issue should be encouraged. However, cohort stud-
ies use broader inclusion criteria and fewer exclusion
criteria than randomised studies do, making results
more generalisable for clinical practice.
Prior to a traveller’s attendance, all travellers are in-
formed about the costs, so when travellers say that they
do not want to be vaccinated, they will also pay the med-
ical visit, so it is never an economical reason for why
they are not vaccinated. The reasons for not vaccinating
are that the inoculations are not mandatory to enter to
their destination countries, or they need to receive dif-
ferent or consecutive doses (for example, for rabies).
They say that they cannot come again to the travel clinic
due to work limitations to obtain a free day for a med-
ical visit.
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Despite these limitations, the strengths of this study
were that the cohort was properly selected and consti-
tuted a large number of participants; the study design
was appropriate and the methodology of the study was
accurate, reducing problems of bias.
Conclusions
Given the rise in the number of international migrants, a
significant proportion of travellers currently constitute VFR
travellers, and the proportion of subjects travelling outside
their home country (to return to their country of origin) is
expected to increase. Findings from this study described
differences in pre-travel care received between VFR and
non-VFR travellers, with the latter showing lower rates of
completion of recommended vaccinations, in spite of their
increased risk for travel-related health problems and dis-
eases. More research is needed in order to investigate fac-
tors that may explain the found differences.
In this frame, the pre-travel care of VFR travellers
must be taken as a growing challenge to travel and pre-
ventive medicine.
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